A PYMNTS Company

UK: Aspen found guilty of antitrust activities against the NHS

By  |  August 14, 2019

A probe from the UK’s competition watchdog has resulted in an £8 million (US$9.7 million) payment from Aspen Pharma to Britain’s National Health Service (NHS).

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The South African drugmaker agreed to make the payment, as part of a wider package, after the Competition and Markets Authority uncovered “anti-competitive arrangements” regarding the supply of the life-saving medicine fludrocortisone.

    The drug is primarily used to treat primary or secondary adrenal insufficiency, commonly known as Addison’s disease.

    The payment to the NHS and the firm’s admission of illegality, as well as an additional fine of up to £2.1 million (US$2.5 million), will forestall any legal action from the UK government.

    Full Content: Gov UK

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.